Clinical Trial Update: Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating regorafenib plus FOLFIRI versus placebo plus FOLFIRI as second-line therapy in metastatic colorectal cancer; completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• Regorafenib (regorafenib)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Colorectal Cancer Metastatic | Phase 2 | Status: COMPLETED | Results posted: 2018-02-28